Compare Wix.Com Ltd (WIX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wix.Com Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Wix.Com Ltd trades at $73.87 (market cap $3.11B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| WIX | XBI | |
|---|---|---|
Market Cap | $3.11B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $184.24 | $169.55 |
52-Week Low | $40.43 | $93.43 |
Enterprise Value | $4.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WIX trades at $72.72, down 4.58% amid technical bearish signals and multiple securities class action lawsuits. The company shows revenue growth to $1.99B in 2025 but faces profitability challenges with a negative net income margin of -8.19%. Recent earnings were mixed with Q1 2026 missing expectations while Q2 2026 beat estimates. Cash flow trends show operational strength but significant investing outflows.
Analyst consensus remains positive with 63% buy ratings and $73.36 price target, but legal risks and competitive pressures create headwinds. The stock presents a high-risk opportunity with potential upside if legal issues resolve and AI product execution improves, though current technical weakness suggests caution.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
